Patisiran, an RNAi therapeutic for patients with hereditary transthyretin‐mediated amyloidosis: Sub‐analysis in Japanese patients from the APOLLO study
Open Access
- 1 May 2020
- journal article
- research article
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 8 (5), 251-260
- https://doi.org/10.1111/ncn3.12396
Abstract
No abstract availableKeywords
Funding Information
- Alnylam Pharmaceuticals
This publication has 33 references indexed in Scilit:
- Safety and Efficacy of RNAi Therapy for Transthyretin AmyloidosisThe New England Journal of Medicine, 2013
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosisCurrent Medical Research and Opinion, 2012
- COMPASS 31: A Refined and Abbreviated Composite Autonomic Symptom ScoreMayo Clinic Proceedings, 2012
- Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areasJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathiesNeurology, 2011
- Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in JapanBrain, 1999
- Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)‐type I in Póvoa do Varzim and Vila do Conde (north of Portugal)American Journal of Medical Genetics, 1995
- Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.Journal of Medical Genetics, 1994
- Familial Amyloidotic Polyneuropathy in Sweden: Geographical Distribution, Age of Onset, and PrevalenceHuman Heredity, 1993